Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Factors in the Tumor Microenvironment Promote Cancer Growth and Metastasis

By BiotechDaily International staff writers
Posted on 13 Aug 2014
Print article
Cancer researchers have found that procancerous HSF1 (Heat shock factor 1) drives a transcriptional program in cancer-associated fibroblasts (CAFs) that complements, yet is completely different from, the program it drives in adjacent cancer cells.

Stromal cells within the tumor microenvironment are essential for tumor progression and metastasis, but little is known about the factors that drive the transcriptional reprogramming of stromal cells within tumors. Investigators at the Whitehead Institute for Biomedical Research (Cambridge, MA, USA) recently reported that the transcriptional regulator heat shock factor 1 (HSF1) was frequently activated in cancer-associated fibroblasts (CAFs), where it was a potent enabler of malignancy. HSF1 activity was found in a variety of human tumors, including breast, lung, skin, esophageal, colon, and prostate cancers.

HSF1 is the major regulator of heat shock protein transcription in eukaryotes. In the absence of cellular stress, HSF1 is inhibited by association with the heat shock proteins Hsp40/Hsp70 and Hsp90 and is therefore not active. Cellular stresses, such as increased temperature, can cause misfolding of proteins in the cell. Heat shock proteins bind to the misfolded proteins and dissociate from HSF1. This allows HSF1 to form trimers and translocate to the cell nucleus where it is hyperphosphorylated, binds to DNA containing heat shock elements, and activates transcription.

The investigators reported in the July 31, 2014, issue of the journal Cell that analysis of tumor samples from breast cancer and non-small-cell lung cancer patients revealed that HSF1 activation in the stroma was associated with poor patient outcomes, including reduced disease-free survival and overall survival. Thus, stromal HSF1 is considered to be a possible biomarker for cancer diagnosis and prognosis as well as a potential drug target.

“This is actually a beautiful example of evolution,” said Dr. Ruth Scherz-Shouval, a postdoctoral researcher at the Whitehead Institute for Biomedical Research. “It is recognizing that the tumor is like an organism that adheres to evolutionary principles. HSF1 has been highly conserved over time, supporting the survival of organisms ranging from yeast to human, so it makes sense that it is coopted here. Both cancer cells and the microenvironment are sensing changes in the tumor and responding, signaling to one another to help the “organism,” albeit to the detriment of the host. These are different programs, but they are both controlled by HSF1 and serve the same purpose.”

“It is important to find HSF1 operating this way in the stroma,” said Dr. Scherz-Shouval. “The tumor microenvironment tends to be more genetically stable and less prone to mutation, suggesting that even if cancer cells could mutate to evade therapeutic disruption of HSF1, supportive cells in the stroma could still be susceptible.”

Related Links:

Whitehead Institute for Biomedical Research



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.